A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making

被引：9

作者：

Sanft, Tara ^{[1
]}

Berkowitz, Alyssa ^{[1
]}

Schroeder, Brock ^{[2
]}

Hatzis, Christos ^{[1
]}

Schnabel, Catherine A. ^{[2
]}

Brufsky, Adam ^{[3
]}

Gustavsen, Gary ^{[4
]}

Pusztai, Lajos ^{[1
]}

van Londen, G. J. ^{[3
]}

机构：

[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA

[2] Biotheranost Inc, San Diego, CA 92121 USA

[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA

[4] Hlth Adv LLC, Weston, MA 02493 USA

来源：

BREAST CANCER MANAGEMENT | 2019年 / 8卷 / 01期

关键词：

ADJUVANT THERAPY; COST-EFFECTIVENESS; RECURRENCE SCORE; TAMOXIFEN; WOMEN; LETROZOLE; ADHERENCE; PALBOCICLIB; PERSISTENCE; PREDICTION;

D O I：

10.2217/bmt-2019-0001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To prospectively assess the impact of gene expression-based assay Breast Cancer Index (BCI) on extended endocrine therapy (EET) decision-making. Patients & methods: The BCI-tested samples from primary tumors (Stage I-III, hormone receptor positive breast cancer, >3.5 year endocrine therapy). Patients and physicians completed questionnaires on EET preferences and decision conflict. Using these data, a fact-based economic model was developed to project the cost impact of BCI. Results: The BCI results affected treatment recommendations for 42/141 patients (overall mean, 62 year; 83% postmenopausal; 63% Stage I). Patient decision conflict decreased pre- to post-test. The BCI-related projected net savings (US$5190/patient) was robust under sensitivity analysis. Conclusion: Incorporating BCI into clinical practice meaningfully impacted physician EET recommendations and decreased patient decision conflict, with projected cost savings.

引用

页数：12

共 38 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2]

[Anonymous], IBM MICR 2 0 EL VERS

[3]

[Anonymous], 2009, NEHI RES BRIEF

[4]

[Anonymous], 2013, J CLIN ONCOL, V31, P5, DOI [10.1200/jco.2013.31.18_suppl.5, 10.1200/jco.2013.31.18suppl.5]

[5] A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer [J].

Barron, T. I. ;

Cahir, C. ;

Sharp, L. ;

Bennett, K. .

BRITISH JOURNAL OF CANCER, 2013, 109 (06) :1513-1521

[6] Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) [J].

Blok, Erik J. ;

Kroep, Judith R. ;

Kranenbarg, Elma Meershoek-Klein ;

Duijm-de Carpentier, Marjolijn ;

Putter, Hein ;

van den Bosch, Joan ;

Maartense, Eduard ;

van Leeuwen-Stok, A. Elise ;

Liefers, Gerrit-Jan ;

Nortier, Johan W. R. ;

Rutgers, Emiel J. Th. ;

van de Velde, Cornelis J. H. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (01) :40-48

[7] A Review and Classification of Approaches for Dealing with Uncertainty in Multi-Criteria Decision Analysis for Healthcare Decisions [J].

Broekhuizen, Henk ;

Groothuis-Oudshoorn, Catharina G. M. ;

van Til, Janine A. ;

Hummel, J. Marjan ;

IJzerman, Maarten J. .

PHARMACOECONOMICS, 2015, 33 (05) :445-455

[8]

Clarke M, 1998, LANCET, V351, P1451

[9] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J].

Davies, Christina ;

Pan, Hongchao ;

Godwin, Jon ;

Gray, Richard ;

Arriagada, Rodrigo ;

Raina, Vinod ;

Abraham, Mirta ;

Medeiros Alencar, Victor Hugo ;

Badran, Atef ;

Bonfill, Xavier ;

Bradbury, Joan ;

Clarke, Michael ;

Collins, Rory ;

Davis, Susan R. ;

Delmestri, Antonella ;

Forbes, John F. ;

Haddad, Peiman ;

Hou, Ming-Feng ;

Inbar, Moshe ;

Khaled, Hussein ;

Kielanowska, Joanna ;

Kwan, Wing-Hong ;

Mathew, Beela S. ;

Mittra, Indraneel ;

Mueller, Bettina ;

Nicolucci, Antonio ;

Peralta, Octavio ;

Pernas, Fany ;

Petruzelka, Lubos ;

Pienkowski, Tadeusz ;

Radhika, Ramachandran ;

Rajan, Balakrishnan ;

Rubach, Maryna T. ;

Tort, Sera ;

Urrutia, Gerard ;

Valentini, Miriam ;

Wang, Yaochen ;

Peto, Richard .

LANCET, 2013, 381 (9869) :805-816

[10] Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years [J].

Goss, P. E. ;

Ingle, J. N. ;

Pritchard, K. I. ;

Robert, N. J. ;

Muss, H. ;

Gralow, J. ;

Gelmon, K. ;

Whelan, T. ;

Strasser-Weippl, K. ;

Rubin, S. ;

Sturtz, K. ;

Wolff, A. C. ;

Winer, E. ;

Hudis, C. ;

Stopeck, A. ;

Beck, J. T. ;

Kaur, J. S. ;

Whelan, K. ;

Tu, D. ;

Parulekar, W. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (03) :209-219

← 1 2 3 4 →